The SSC Crowns 50 Years of Advances

The Superconducting Supercollider, the $6 billion particle accelerator whose construction was just endorsed by the President, is inevitable. The only serious questions surrounding it for the past half dozen years have been when and where. Why inevitable? Because the SSC is the unarguable means of answering the most fundamental scientific questions we can formulate: How are the forces of nature related, and what does that tell us about the underlying structure and behavior of matter? Progress in

Written byKeyworth Iii
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Why inevitable? Because the SSC is the unarguable means of answering the most fundamental scientific questions we can formulate: How are the forces of nature related, and what does that tell us about the underlying structure and behavior of matter? Progress in the past few years has given us increasing confidence that an experimental device of the power of the SSC may finally provide evidence and details of the Grand Unified Theory—the scientific payoff of 75 years of atomic and subatomic physics. And it's also becoming clear that we're ready and impatient to move onto that new level.

I think there are three essential issues that drove the President's decision to recommend funding for the SSC.

First, it is a meticulously thought-out, sound scientific program. It enjoys broad endorsement by the physics community because it so directly meets a compelling need. In the early 1980s, physicists went through painful reassessments ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies